PRAX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PRAX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-03-28), Praxis Precision Medicines's share price is $38.82. Praxis Precision Medicines's Book Value per Share for the quarter that ended in Dec. 2024 was $22.94. Hence, Praxis Precision Medicines's PB Ratio of today is 1.69.
Good Sign:
Praxis Precision Medicines Inc stock PB Ratio (=1.69) is close to 1-year low of 1.62.
The historical rank and industry rank for Praxis Precision Medicines's PB Ratio or its related term are showing as below:
During the past 7 years, Praxis Precision Medicines's highest PB Ratio was 7.70. The lowest was 0.73. And the median was 2.29.
During the past 12 months, Praxis Precision Medicines's average Book Value Per Share Growth Rate was 189.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -34.90% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Praxis Precision Medicines was -34.90% per year. The lowest was -58.70% per year. And the median was -46.80% per year.
The historical data trend for Praxis Precision Medicines's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Praxis Precision Medicines Annual Data | ||||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
PB Ratio | Get a 7-Day Free Trial | 7.32 | 3.56 | 1.54 | 2.81 | 3.36 |
Praxis Precision Medicines Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
PB Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
2.81 | 3.52 | 1.75 | 2.67 | 3.36 |
For the Biotechnology subindustry, Praxis Precision Medicines's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Praxis Precision Medicines's PB Ratio distribution charts can be found below:
* The bar in red indicates where Praxis Precision Medicines's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Praxis Precision Medicines's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Dec. 2024) |
= | 38.82 | / | 22.935 | |
= | 1.69 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Praxis Precision Medicines (NAS:PRAX) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Praxis Precision Medicines's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Alex Nemiroff | officer: General Counsel and Secretary | C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142 |
Lauren Mastrocola | officer: Principal Accounting Officer | C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142 |
Jill Desimone | director | C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110 |
Marcio Souza | officer: Chief Executive Officer | C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
Dean J Mitchell | director | C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164 |
Timothy Edwin Kelly | officer: Chief Financial Officer | C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142 |
Bsof Parallel Master Fund L.p. | 10 percent owner | 345 PARK AVENUE, NEW YORK NY 10154 |
Merit Ester Cudkowicz | director | C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142 |
Jeffrey Chodakewitz | director | C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL ST., SUITE 101, WATERTOWN MA 02472 |
Stefan Vitorovic | director | C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142 |
Blackstone Holdings I/ii Gp L.l.c. | 10 percent owner | C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154 |
William D Young | director | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Stephen A Schwarzman | 10 percent owner | C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154 |
Blackstone Inc. | 10 percent owner | 345 PARK AVENUE, NEW YORK NY 10154 |
Blackstone Group Management L.l.c. | 10 percent owner | C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154 |
From GuruFocus
By GuruFocus News • 02-15-2025
By GuruFocus News • 01-13-2025
By GuruFocus News • 11-15-2024
By GuruFocus News • 11-14-2024
By Marketwired • 02-03-2025
By Marketwired • 03-04-2025
By GuruFocus News • 02-15-2025
By GuruFocus News • 02-28-2025
By Marketwired • 01-06-2025
By GuruFocus News • 01-06-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.